• Clinical Evidence

Can Severe Hypoglycemia be Eliminated? Introducing Estimated Residual Extracellular Insulin (EREI)

Setting: Cohort of 84 community hospitals.

Objective

This retrospective analysis compares incidence of hypoglycemia with and without use of the specialized EndoTool EREI (estimated residual extracellular insulin) adjustment feature.

Setting

Cohort of 84 community hospitals.

Results

  • Incidence of hypoglycemia <40 mg/dL was 63% lower when the EndoTool EREI adjustment feature was enabled.
  • Specifically, hypoglycemia occurred at a rate of one for every 351 patient days of intravenous insulin therapy with the EREI adjustment feature versus one for every 129 patient days without the EREI adjustment feature.

Conclusions

Use of the specialized EndoTool EREI adjustment feature significantly reduces incidence of hypoglycemia without significantly impacting glycemic control.

Objective

This retrospective analysis compares incidence of hypoglycemia with and without use of the specialized EndoTool EREI (estimated residual extracellular insulin) adjustment feature.

Setting

Cohort of 84 community hospitals.

Results
  • Incidence of hypoglycemia <40 mg/dL was 63% lower when the EndoTool EREI adjustment feature was enabled.
  • Specifically, hypoglycemia occurred at a rate of one for every 351 patient days of intravenous insulin therapy with the EREI adjustment feature versus one for every 129 patient days without the EREI adjustment feature.
Conclusions

Use of the specialized EndoTool EREI adjustment feature significantly reduces incidence of hypoglycemia without significantly impacting glycemic control.

References

Authors

W. Patrick Burgess, PhD, MD; Laura Santana, RN; Laurel Fuqua, RN, MSN.

Source

Presented at Annual Diabetes Technology Meeting. Published in Journal of Diabetes Science and Technology, Volume 1, Issue 2, p373.

Year

2019

Quick navigation
Objective
Setting
Results
Conclusions
References
Objective

This retrospective analysis compares incidence of hypoglycemia with and without use of the specialized EndoTool EREI (estimated residual extracellular insulin) adjustment feature.

Setting

Cohort of 84 community hospitals.

Results
  • Incidence of hypoglycemia <40 mg/dL was 63% lower when the EndoTool EREI adjustment feature was enabled.
  • Specifically, hypoglycemia occurred at a rate of one for every 351 patient days of intravenous insulin therapy with the EREI adjustment feature versus one for every 129 patient days without the EREI adjustment feature.
Conclusions

Use of the specialized EndoTool EREI adjustment feature significantly reduces incidence of hypoglycemia without significantly impacting glycemic control.

References

Authors

W. Patrick Burgess, PhD, MD; Laura Santana, RN; Laurel Fuqua, RN, MSN.

Source

Presented at Annual Diabetes Technology Meeting. Published in Journal of Diabetes Science and Technology, Volume 1, Issue 2, p373.

Year

2019

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

The objective of this study was to evaluate the impact of renal insufficiency on hypoglycemia rates in patients treated for Diabetic Ketoacidosis (DKA) utilizing a computerized insulin dosing algorithm.
Image
  • Clinical Evidence

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

20 minute read

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

The objective of this study was to evaluate the impact of different blood glucose (BG) target ranges for IV insulin infusions on inpatient glucose metrics, specifically focusing on hypo and hyperglycemic events, duration of IV insulin therapy, and length of stay (LOS) in the hospital.
Image
  • Clinical Evidence

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

To compare the effectiveness of EndoTool IV in reducing hospital LOS and hypoglycemia rates compared to standard insulin infusion protocols.
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.